228 related articles for article (PubMed ID: 15046536)
1. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond.
Owens MJ
J Clin Psychiatry; 2004; 65 Suppl 4():5-10. PubMed ID: 15046536
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and norepinephrine transporter binding profile of SSRIs.
Gutman DA; Owens MJ
Essent Psychopharmacol; 2006; 7(1):35-41. PubMed ID: 16989291
[TBL] [Abstract][Full Text] [Related]
3. Norepinephrine involvement in antidepressant action.
Frazer A
J Clin Psychiatry; 2000; 61 Suppl 10():25-30. PubMed ID: 10910014
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs.
Lucki I; O'Leary OF
J Clin Psychiatry; 2004; 65 Suppl 4():11-24. PubMed ID: 15046537
[TBL] [Abstract][Full Text] [Related]
5. [Domino principle--monoamines in bottom-view].
Sümegi A
Neuropsychopharmacol Hung; 2008 Jun; 10(3):131-40. PubMed ID: 18956617
[TBL] [Abstract][Full Text] [Related]
6. Role of norepinephrine in depression.
Delgado PL; Moreno FA
J Clin Psychiatry; 2000; 61 Suppl 1():5-12. PubMed ID: 10703757
[TBL] [Abstract][Full Text] [Related]
7. The neuropharmacology of serotonin and noradrenaline in depression.
Nutt DJ
Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S1-12. PubMed ID: 12369606
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies.
Frazer A
J Clin Psychiatry; 2001; 62 Suppl 12():16-23. PubMed ID: 11430614
[TBL] [Abstract][Full Text] [Related]
9. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
10. Noradrenergic versus serotonergic antidepressants: predictors of treatment response.
Schatzberg AF
J Clin Psychiatry; 1998; 59 Suppl 14():15-8. PubMed ID: 9818626
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of antidepressants: selectivity or multiplicity?
Westenberg HG
J Clin Psychiatry; 1999; 60 Suppl 17():4-8; discussion 46-8. PubMed ID: 10446734
[TBL] [Abstract][Full Text] [Related]
12. Monoamine dysfunction and the pathophysiology and treatment of depression.
Charney DS
J Clin Psychiatry; 1998; 59 Suppl 14():11-4. PubMed ID: 9818625
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological principles of antidepressant efficacy.
Schatzberg AF
Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S17-22. PubMed ID: 12404665
[TBL] [Abstract][Full Text] [Related]
14. [Consequences of the monoaminergic systems cross-talk in the antidepressant activity].
Tritschler L; Gaillard R; Gardier AM; David DJ; Guilloux JP
Encephale; 2018 Jun; 44(3):264-273. PubMed ID: 29801770
[TBL] [Abstract][Full Text] [Related]
15. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
16. In the treatment of depression, does selectivity of action matter?
J Clin Psychiatry; 2004; 65 Suppl 4():60-2. PubMed ID: 15046543
[No Abstract] [Full Text] [Related]
17. History and evolution of the monoamine hypothesis of depression.
Hirschfeld RM
J Clin Psychiatry; 2000; 61 Suppl 6():4-6. PubMed ID: 10775017
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for a pure noradrenergic drug in the treatment of depression?
Montgomery SA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
20. Noradrenergic approaches to antidepressant therapy.
Gorman JM; Sullivan G
J Clin Psychiatry; 2000; 61 Suppl 1():13-6. PubMed ID: 10703758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
